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Abstract
Background:
Myxopapillary ependymoma (MPE) with anaplastic features is extremely rare, with only three case reports in the
literature.
Case Description:
We report the case of a MPE with anaplastic features in a 24-year-old female who presented with a dominant lumbar
mass along with intracranial and sacral metastases. Upon gross total resection of the dominant tumor located at L2-
L3, it appeared to arise from the filum terminale, and had a solid component in addition to soft or necrotic areas.
Histologically, the tumor was composed of the two classic components of MPE: (1) low-grade ependymal cells
surrounding blood vessels, producing the papillary appearance and (2) perivascular myxoid material between blood
vessels and ependymal cells, creating the myxopapillary appearance. The high-grade anaplastic component showed
hypercellularity, brisk mitotic rate, and vascular proliferation, with frequent pleomorphic cells and atypical mitotic
figures. It was positive for vimentin and glial fibrillary acidic protein (GFAP); negative for epithelial membrane
antigen (EMA), CAM5.2, creatine kinase 7 (CK7), CK20; and the MIB-1 index (Ki-67) was 8–38%. Ten months
after initial resection, follow-up magnetic resonance imaging revealed new lesions in (1) the hypothalamus, (2) the
left pons, and (3) the left medial temporal lobe, which were treated with radiosurgery. Eight months later (18 months
from initial surgery), the patient underwent thoracic laminectomy for a large leptomeningeal metastasis at T6 and T8.
Conclusion:
The present case of MPE with anaplastic features is the fourth case on record in the medical literature.
Keywords: Anaplastic ependymoma, myxopapillary ependymoma, myxopapillary ependymoma with anaplastic
features
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INTRODUCTION
Ependymomas are primary central nervous system (CNS) tumors that arise from the ependymal cells lining the
choroid plexus, the white matter adjacent to the angulated ventricles, and the central canal of the spinal cord. In the
2016 World Health Organization (WHO) classification of CNS tumors, ependymal tumors are divided into five major
subtypes: myxopapillary ependymoma (MPE) and sub-ependymoma (grade I), classic ependymoma (grade II), RELA
fusion-protein positive ependymoma (grade II or III), and anaplastic ependymoma (grade III).[15]
MPEs are usually benign, slow growing gliomas that have been primarily described in the conus-cauda equina-filum
terminale region, though rare occurrences in the cervico-thoracic spinal cord, lateral ventricle, and brain parenchyma
have been reported.[1,14,19,20,23]
Distant metastases to brain parenchyma and other organs have also been reported.[8,12,13,16,18,21,22,24,25,26]
They differ from other ependymomas morphologically and biologically, and frequently require immunohistochemical
analysis in order to differentiate them from phenotypically similar chordomas or chondrosarcomas.[20] Average age
of presentation is 36 years, with a significant male predilection (2.2:1).[17]
Anaplasia in ependymomas is usually defined by the presence of anaplastic features, such as hypercellularity,
frequent mitotic figures, pseudopalisading necrosis, vascular proliferation, and cellular as well as nuclear
pleomorphism.[15] However, histologic criteria for the classification and grading of anaplasia in ependymomas has
historically been and remains a contentious issue, which ultimately makes their diagnosis and prognosis subjective
and difficult. These tumors are usually locally invasive, have a higher propensity to spread to other areas of the
neuraxis via cerebrospinal fluid pathways, and have higher rates of tumor recurrence and decreased rates of survival.
[6,17]
We report the case of a MPE with anaplastic features in a 24-year-old female. Clinical, histopathological, and
immunohistochemical findings are hereby described.
CASE REPORT
History and examination
A 24-year-old female presented with acute on chronic exacerbation of several months of back pain with new right
radicular pain in the right thigh and lateral leg.
On physical examination, the patient was a well-developed, well-appearing young female in no acute distress. She did
not have any cutaneous lesions, including axillary freckling, café au lait spots, or cutaneous neurofibromas. Her
neurologic examination was unremarkable with intact nerve function; similarly, her motor examination was
unremarkable with 5/5 motor strength in all extremities.
Magnetic resonance imaging (MRI) of the lumbar spine with and without contrast demonstrated an enhancing mass
occupying the majority of the spinal canal from L2-L3 [Figure 1a]. Because of the clinical impression of
ependymoma, preoperative pan-imaging of the neuraxis was obtained, including MRI of the brain, cervical, and
thoracic spine. These demonstrated additional lesions at the time of diagnosis, including bilateral internal auditory
canal enhancement, a small focus of enhancement in the left tectum, and an apparent drop metastasis to the sacrum
[Figure 1a–c].
Operation
A lumbar laminectomy at the level of L2-L3 was performed with gross total resection of the dominant lumbar tumor
achieved. At surgery, the tumor appeared to be grossly necrotic, appeared to arise from the filum terminale, and had a
solid component in addition to the soft or necrotic areas.
Histopathological examination
Low-grade areas of tumor [Figure 2a] have classic histology of ependymal cells surrounding blood vessels producing
a somewhat papillary appearance. Perivascular myxoid material between the blood vessels and ependymal cells
create the classic myxopapillary appearance.
High-grade anaplastic areas of tumor [Figure 2b] show hypercellularity, brisk mitotic rate, and vascular proliferation.
Pleomorphic cells and atypical mitotic figures are frequently seen. The MIB-1 index is high. Immunohistochemical
profile is as follows: Positive for vimentin and GFAP [Figure 2c]; Negative for EMA, CAM5.2, CK7, CK20 (not
shown); MIB-1 index (Ki-67) 8–38% [Figure 2d].
The combination of areas of typical MPE-appearing tumor interspersed with areas of ependymoma with anaplastic or
high-grade features was consistent with a diagnosis of MPE with anaplastic features.
Postoperative course
Postoperatively, the patient did well without any new neurologic deficits; bladder and bowel functions were intact,
and the patient had full motor strength in bilateral lower extremities. Postoperative MRI confirmed gross total
resection of the tumor.
Given the presence of anaplastic or malignant-appearing tumor on histopathology, and the presence of disseminated
metastases at presentation, craniospinal radiation was recommended. However, the patient refused, and proceeded
with external beam radiation to the tumor bed in the lumbar spine only. Initially, she refused any treatment for her
cranial metastases, until progression of intracranial disease was documented on follow-up MRI. Again, the patient
refused craniospinal radiation, opting for stereotactic radiosurgery to the growing lesions. Ten months after her
surgical resection, the patient therefore underwent CyberKnife radiosurgery to five intracranial lesions: (1) the lesion
in the hypothalamus, (2) the lesion in the right internal auditory canal, (3) a new left pontine lesion, (4) the left tectum
lesion, and (5) a new left medial temporal lesion. The hypothalamic lesion was treated with a dose of 25 gray in 5
fractions, and the remainder of the lesions were treated in 3 fractions of 8 gray each. The patient was followed with
serial MRIs every 3 months and again demonstrated progression of both intracranial and spinal disease. At 18 months
postoperation from her initial surgery, the patient underwent thoracic laminectomy for a large metastasis at T6 and T8
[Figure 3]. At surgery, it was evident that multiple leptomeningeal metastases had coalesced into a larger tumor,
however, there were also multiple additional leptomeningeal foci of disease noted. The patient was again referred for
craniospinal radiation and/or potential chemotherapy.
DISCUSSION
MPE with anaplastic features is a rare occurrence, with only three case reports in the literature [Table 1].[3,4,5]
Similar to the previous three reports, the present case shows a dominant mass arising from the spinal column.
However, widespread presence of metastases at diagnosis as well as rapid progression is noteworthy in our case. It is
unclear as to why this present case had such aggressive progression of disease. The MIB-1 (Ki-67) index of 8–38% is
similar to the previous three reports, two of which had no recurrence.
The immunohistochemical description of MPE has been reported, which consist of positivity for GFAP and vimentin,
consistent with the present case.[2,7,20]
Conventional MPE have a favorable overall survival, but despite their low-grade designation, almost half of all
patients experience local recurrence (2–15 years after operation), irrespective of adequate excision.[1,10,20]
Recurrences can be accompanied with dissemination, with most metastases restricted regionally within the spine,
although rare cranial metastases have been reported.[1] Many of these patients can undergo salvage therapy with
radiation. As a result, frequent surveillance scanning of patients with MPE is recommended to identify recurrent
disease early.
The 5-year survival rate of patients with anaplastic ependymoma, on the other hand, has been reported to be less than
20%. Radiotherapy following partial excision is then recommended.
Grading of ependymoma is currently difficult and of questionable clinical utility under the current WHO guidelines.
[9] For anaplastic ependymoma specifically, Ho et al. had put forward a prognostic calculator based on a
histopathologic score that takes into account mitoses (>= 4/10 per high-power field), hypercellularity, endothelial
proliferation, necrosis. They furthermore proposed that anaplastic ependymoma could be diagnosed by the presence
of two of those parameters.[11] However, the classification of CNS tumors is moving toward a more molecularly
oriented classification scheme, as reflected in the 2016 WHO classification of CNS tumors.[15] So far, the RELA
fusion-protein positive ependymoma is the only molecularly classified ependymoma. Determination of the RELA
fusion-protein status in this present case was not feasible.
CONCLUSIONS
MPE is a benign tumor that has the potential for malignant degeneration. Although MPE is a WHO grade 1 tumor,
cerebrospinal fluid metastases at the time of initial diagnosis is well reported. In contrast, other features of
malignancy, including high-grade anaplastic histology, are rare, but when occurring is associated with an aggressive
clinical course similar to that of nonmyxopapillary (high grade) ependymoma. The management of patients with
myxopapiallry ependymoma should take into account the possibility of malignant transformation/degeneration.
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Figures and Tables
Figure 1
(a) Contrast enhanced sagittal T1-weighted magnetic resonance imaging demonstrates a homogeneously enhancing mass centered on
L2-3 as well as a small sacra drop metastasis in the sacrum (arrowhead). Axial T1 contrast enhanced MRI demonstrates bilateral
enhancement in the internal auditory canals, and a small enhancing focus was identified in the region of the left tectum (panels b and
c, respectively)
Figure 2
Low magnification view (panel a) demonstrating typical low-grade myxopapillary ependymoma including papillary appearance and
fibrovascular cores. Other areas of tumor (panel b, shown under high magnification) demonstrate anaplasia and cellular atypia typical
of high-grade tumor. Tumor specimen was diffusely positive for GFAP staining, indicating a neuronal differentiation, and
demonstrated a high Ki-67 index (panels c and d, respectively)
Figure 3
Axial and sagittal contrast enhanced T1-weighted MRI showing large enhancing mass within the thoracic spine causing compression
of the thoracic spinal cord (a and b, respectively). Postoperative sagittal MRI demonstrates gross total resection of enhancing mass
(panel c) MRI, magnetic resonance imaging
Table 1
Clinical findings and outcomes in three previously reported cases of myxopapillary ependymoma with
anaplastic features
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